UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/808,368	03/25/2004	Andreas Bergmann	2582.024A	4724
KATHY SMITH DIAS, ESQ. HESLIN ROTHENBERG FARLEY & MESITI P.C.			EXAMINER	
			MERTZ, PREMA MARIA	
5 COLUMBIA CIRCLE ALBANY, NY 12203-5160			ART UNIT	PAPER NUMBER
			1646	
			MAIL DATE	DELIVERY MODE
			06/27/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
Office Action Summary		10/808,368	BERGMANN ET AL.			
		Examiner	Art Unit			
		Prema M. Mertz	1646			
Period fo	The MAILING DATE of this communication ap or Reply	opears on the cover sheet with the	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) 又	Responsive to communication(s) filed on 21 I	May 2008				
-		is action is non-final.				
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
٠,١	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposit	on of Claims					
4)🖂	☑ Claim(s) <u>8-10</u> is/are pending in the application.					
-	4a) Of the above claim(s) is/are withdrawn from consideration.					
	5) Claim(s) is/are allowed.					
	6)⊠ Claim(s) <u>8-10</u> is/are rejected.					
	Claim(s) is/are objected to.					
-	Claim(s) are subject to restriction and/	or election requirement.				
Applicat	ion Papers					
9)□	The specification is objected to by the Examin	ner.				
•	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
٠٠/۵	Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority ι	ınder 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
2) Notice (3) Inform	t(s) te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	4) Interview Summar Paper No(s)/Mail [5) Notice of Informal 6) Other:	Date			

Application/Control Number: 10/808,368 Page 2

Art Unit: 1646

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5/21/08 has been entered.

Claims 8-10 are pending and under consideration by the Examiner.

Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

2a. Claims 8-10 are rejected under 35 U.S.C. 103(a) as unpatentable over Lubbesmeyer et al (1988) in view of U.S. Patent No. 5,639,617 ('617 patent) and DRG Instruments GmbH.

This rejection is maintained for reasons of record set forth at pages 2-4 of the previous Office action (11/21/2007), and the advisory action (5/1/08).

Lubbesmeyer et al teach detection of sepsis in sheep by an immunoassay of plasma in the sheep in which ANF is detected (see abstract; Figure 1, page R568). The concentration of ANF was 13-fold higher within 2 hours after endotoxin administration (abstract, page R568, column 2, second para).

US Patent No. '617 teaches a method for the detection of sepsis by obtaining serum from the individual and using an antibody selective to pro-calcitonin to determine the level of pro-calcitonin relative to healthy individuals (see abstract; column 3, lines 27-60; column 6, Example 1, lines 41-65; column 8, lines 30-41).

DRG Instruments Gmbh (see Applicants specification, page 18, lines 27-30; page 19, lines 1-9) teaches a kit for determining the level of pro-ANF and other pro-hormones.

Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to modify the method of Lubbesmeyer in view of the '617 patent by using antibodies to pro-ANF as described by DRG Instruments GmbH because the '617 patent teaches that antibodies to the pro-hormone are selective and when used in determining the levels of pro-hormone increase are a clear and valuable way for detection of sepsis. Furthermore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to modify the method of Lubbesmeyer in view of the '617 patent by using in the claimed method, antibodies to pro-ANF as well as antibodies to procalcitonin for the detection of

Application/Control Number: 10/808,368 Page 4

Art Unit: 1646

sepsis, because the '617 patent teaches that determining the level of procalcitonin is indicative of

the detection of sepsis (for diagnosis and assessing the progression of sepsis).

Since Applicants have failed to submit arguments to demonstrate an error in the rejection

by the Examiner or amend claims 8-10 in response to the action mailed 5/1/08, this rejection is

maintained for reasons of record.

Conclusion

No claim is allowed.

Claims 8-10 are rejected.

All claims are drawn to the same invention claimed in the parent application prior to the

filing of this request for continued examination (RCE) under 37 CFR 1.114 and could have been

finally rejected on the grounds and art of record in the next Office action. Accordingly, THIS

ACTION IS MADE FINAL even though it is a first action after the filing under 37 CFR 1.114.

Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

MONTHS of the mailing date of this final action and the advisory action is not mailed until after

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37

CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will

the statutory period for reply expire later than SIX MONTHS from the mailing date of this final

action.

Advisory Information

Application/Control Number: 10/808,368

Art Unit: 1646

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on (571) 272-0835.

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/<u>Prema Mertz</u>/ Primary Examiner Art Unit 1646 Page 5